Long-term effects of selective and nonselective endothelin receptor antagonists in mice with heart failure

Journal of Cardiac Failure

Volumn 8, Issue 4, 2002, Pages 254-261

  Cavasin, Maria A ^a   Carretero, Oscar A ^a   Yang, Fang ^a   Oja Tebbe, Nancy ^a   Peng, Hongmei ^a   Yang, Xiao Ping ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Cardiac function; Echocardiography; Remodeling

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE REMODELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; VASCULAR SMOOTH MUSCLE;

EID: 85047698949     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2002.0804254     Document Type: Article

References (36)

1. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci U S A 1989;86-3915-3918
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415
3. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC Jr: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67: 719-724
4. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr: Increased endothelin in experimental heart failure. Circulation 1990;82:2226-2230
5. Gray GA: Pharmacological characterization of endothelin receptors. In Gray GA, Webb DJ, eds: Molecular biology and pharmacology of the endothelins. RG Landes, Austin, TX, 1995, pp. 61-94
6. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995;92:357-363
7. Tschudi MR, Lüscher TF: Characterization of contractile endothelin receptors and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun 1994;204:685-690
8. Ammarguellat F, Larouche I, Schiffrin EL: Myocardial fibrosis in DOCA-salt hypertensive rats: effects of endothelin ET(A) receptor antagonism. Circulation 2001;103: 319-324
9. B receptor subtypes are involved in the in vivo aldosterone secretagogue effect of endothelin-1 in rats. Res Exp Med 1996;196:145-152
10. B receptor subtypes. J Clin Endocrinol Metab 1997;82:3445-3449
11. B receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;186:867-873
12. De Nucci G, Thomas R, D'Orleans-Juste J, Antunes E, Wagner C, Warner TD, Vane JR: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988;85:9797-9800
13. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999;33:581-585
14. Allcock GH, Wagner TD, Vane JR: Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat. Use of selective antagonists. Br J Pharmacol 1995;116:2482-2486
15. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer H-H, Bauer C: Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999;33:816-822
16. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C: Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-1982
17. Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Goldstein S, Sabbah HN: Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000;35:222-229
18. Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP, Renet S, Wessale J, Opgenorth T, Thuillez C: Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation 2000;102:491-493
19. 1 antagonist, and combined treatment in mice with heart failure. J Cardiovasc Pharmacol 2000;36:472-480
20. Yang X-P, Liu Y-H, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA: Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 2000;88:1072-1079
21. Potter GS, Johnson RJ, Fink GD: Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997;30:1578-1584
22. Yang X-P, Liu Y-H, Shesely EG, Bulagannawar M, Liu F, Carretero OA: Endothelial nitric oxide gene knockout mice. Cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 1999;34:24-30
23. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-1935
24. Sokol RJ, McKim JM Jr, Goff MC, Ruyle SZ, Devereaux MW, Han D, Packer L, Everson G: Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 1998;114:164-174
25. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802
26. Rossi GP, Sacchetto A, Cesari M, Pessina AC: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-307
27. Berthold H, Münter K, Just A, Kirchheim HR, Ehmke H: Stimulation of the renin-angiotensin system by endothelin subtype A receptor blockade in conscious dogs. Hypertension 1999;33:1420-1424.
28. Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M: Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000;47:274-283
29. A receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000;35:992-997
30. Sütsch G, Kiowski W, Yan X-W, Hunziker P, Christen S, Strobel W, Kim J-H, Rickenbacher P, Bertel O: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-2268
31. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94:2131-2137
32. Inada T, Fujiwara H, Hasegawa K, Araki M, Yamauchi-Kohno R, Yabana H, Fujiwara T, Tanaka M, Sasayama S: Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters. J Am Coll Cardiol 1999;33:565-571
33. Barton M, Luscher TF: Endothelin antagonists for hypertension and renal disease. Curr Opin Nephrol Hypertens 1999;8:549-556
34. B receptor mediated clearance of endothelin-1? Life Sci 1998;62:185-193
35. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Böhm M: Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999;99:2118-2123
36. Herizi A, Jover B, Bouriquet N, Mimran A: Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998;31:10-14